Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
1.160
+0.040 (3.57%)
At close: May 28, 2025, 4:00 PM
1.170
+0.010 (0.86%)
After-hours: May 28, 2025, 5:15 PM EDT
Gossamer Bio Revenue
Gossamer Bio had revenue of $9.89M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $124.59M. In the year 2024, Gossamer Bio had annual revenue of $114.70M.
Revenue (ttm)
$124.59M
Revenue Growth
n/a
P/S Ratio
2.04
Revenue / Employee
$859,241
Employees
145
Market Cap
263.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GOSS News
- 12 days ago - Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 13 days ago - Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Business Wire
- 16 days ago - Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 - Business Wire
- 21 days ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference - Business Wire
- 2 months ago - Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - Business Wire
- 3 months ago - Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD - Seeking Alpha
- 4 months ago - Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress - Business Wire